Integra LifeSciences (IART) Stock Could Be Reasonable Despite A 77% Slump

Integra LifeSciences Holdings has had a tough longer run, even with a better patch more recently, which puts fresh focus on what investors are really paying for its cash flows today. With the stock closing at US$15.69, the question is whether that price is aligned with what the business can generate in cash over time.

• The share price has fallen about 77.4% over the past 5 years, which puts the cash flow outlook under a harsher spotlight than short term moves alone would suggest.
• For a medical technology group like Integra LifeSciences, future cash generation hinges on how efficiently it turns sales into free cash flow while funding product development and any required investment in its manufacturing base.
• Prefer to judge Integra LifeSciences Holdings on sales? See what Integra LifeSciences Holdings's 0.7x P/S says about the price.

For investors, the debate is whether Integra LifeSciences' recent share price level is adequately supported by the cash flows that the intrinsic value model is built on.

If you are weighing Integra LifeSciences Holdings through the lens of its cash flows, it can help to compare it with a focused list of other companies using 34 high quality undervalued stocks.

Is Integra LifeSciences Holdings Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) model here looks at what Integra LifeSciences Holdings might generate in free cash over time and then compares that to today’s US$15.69 share price. On the latest twelve month view the business reported a free cash flow loss of about $10.3 million, so the model assumes conditions improve from a weak starting point rather than steady performance.

Analyst inputs in the DCF feed in recovering free cash flows, with projected annual figures moving into positive territory and then building through the next decade. That pattern matters for Integra LifeSciences because the valuation leans on the idea that current cash pressures are not permanent and that future years carry more weight once discounted back to today. The result is that the DCF projections put Integra LifeSciences Holdings' estimated intrinsic value substantially above the current share price, which gives you a sense of how the model views the stock at US$15.69 compared with its cash flow profile over time. Find out what Integra LifeSciences Holdings could be worth using our Discounted Cash Flow (DCF) estimate.

The Integra LifeSciences Holdings Narrative: What Would Justify Today's Price?

Narratives for Integra LifeSciences Holdings pick up where that valuation puzzle leaves off, by spelling out which specific paths for future growth, margins and earnings would need to play out for the current price to look too low or too high. Each one ties a number to a clear view on where Integra LifeSciences Holdings' growth, profitability and risks might head next, which you can track over time on Simply Wall St's Community page as new information comes through.

One of the top community narratives on Integra LifeSciences Holdings: 42% undervalued

"The operating model transformation and culture of continuous improvement, combined with recent annualized cost savings initiatives, set up a virtuous cycle of operating leverage..."

Discover why this Narrative puts Integra LifeSciences Holdings at 42% undervalued.

The Integra LifeSciences share price is only one part of the investment story

Share valuation is just one angle for Integra LifeSciences Holdings, because the research checks also highlight specific concerns that could matter for your risk assessment, and those details deserve a closer look. Take a closer look at 1 major warning sign before settling on a valuation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com